When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan

The addition of anti-angiogenesis drugs to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) or chemotherapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC) can improve disease control. We conducted a study to evaluate the efficacy of combination therapeutic str...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2022-05, Vol.22 (1), p.571-571, Article 571
Main Authors: Chen, Chieh-Lung, Wang, Sing-Ting, Liao, Wei-Chih, Chen, Chia-Hung, Tu, Chih-Yen, Chen, Hung-Jen, Hsia, Te-Chun, Cheng, Wen-Chien
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis inhibitors
Anti-angiogenesis
Cancer therapies
Chemotherapy
Clinical outcomes
Clinical trials
Disease control
Drug therapy
Drug therapy, Combination
Enzyme inhibitors
Epidermal growth factor
Epidermal growth factor receptor (EGFR)
Epidermal growth factor receptors
Genetic aspects
Liver
Lung cancer
Lung cancer, Non-small cell
Medical prognosis
Metastases
Metastasis
Mutants
Mutation
Non-small cell lung carcinoma
Non–small cell lung cancer (NSCLC)
Patient outcomes
Patients
Protein-tyrosine kinase
Small cell lung carcinoma
Tomography
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The addition of anti-angiogenesis drugs to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) or chemotherapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC) can improve disease control. We conducted a study to evaluate the efficacy of combination therapeutic strategies and identify patients who could benefit from combination therapy. This study enrolled patients with stage IV EGFR-mutant NSCLC treated with first-line EGFR-TKIs between January 2014 and December 2020. We divided patients into three groups: patients who received an anti-angiogenesis drug as first-line combination therapy, those who received an anti-angiogenesis drug as further-line combination therapy, and those with no anti-angiogenesis therapy. A total of 204 patients were enrolled in the final analysis. Progression-free survival (PFS) in patients receiving first-line anti-angiogenesis plus EGFR-TKI combination therapy was longer (18.2 months) than those treated with first-line EGFR-TKI monotherapy (10.0 months for both, p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-022-09672-4